GSK1605786 GSK modified-process: formulation D ( DrugBank: - )

---

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
96	クローン病	1

96. クローン病

---

臨床試験数 : 2,442 /  薬物数 : 1,278 - (DrugBank : 248) / 標的遺伝子数 : 142 - 標的パスウェイ数 : 209

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01114607 (ClinicalTrials.gov)	May 5, 2010	29/4/2010	A Study to Assess the Relative Bioavailability of Four New Formulations of GSK1605786 in Healthy Subjects	A Single Dose, Randomized, Five-Period Crossover Study to Assess the Relative Bioavailability of Four New Formulations of the CCR9 Receptor Antagonist GSK1605786A (CCX282) in Healthy Male and Female Subjects	Crohn's Disease	Drug: GSK1605786 ChemoCentryx: formulation A;Drug: GSK1605786 GSK: formulation B;Drug: GSK1605786 GSK direct-fill: formulation C;Drug: GSK1605786 GSK modified-process: formulation D;Drug: GSK1605786 GSK tablet: formulation E	GlaxoSmithKline	NULL	Completed	18 Years	55 Years	All	24	Phase 1	United States